Unum Therapeutics Inc. plans to offer up to about $86.3 million of its common shares through an IPO.
The company plans to list its stock on the Nasdaq Global Market under the symbol UNUM.
Morgan Stanley & Co. LLC, Cowen and Co. LLC and Wedbush Securities Inc. are underwriting the IPO.
Cambridge, Mass.-based Unum Therapeutics develops a proprietary therapy for multiple cancers.
The company's antibody-coupled T-cell receptor, or ACTR protein, kills tumors identified by separately administered antibodies. Unum Therapeutics expects the ACTR platform to universally treat cancers, as it is not bound to a single type of tumor-targeting antibody.
